Study Links DCCBs to 33% Higher Kidney Risk in 31,031 Diabetic Patients
Updated
Updated · SciTechDaily · Jun 16
Study Links DCCBs to 33% Higher Kidney Risk in 31,031 Diabetic Patients
2 articles · Updated · SciTechDaily · Jun 16
Summary
31,031 adults with type 2 diabetes and diabetic kidney disease showed a 33% higher risk of major adverse kidney events when taking dihydropyridine calcium-channel blockers alongside RAS and SGLT2 drugs.
3.5 years of median follow-up found the excess risk persisted after adjusting for clinical and demographic differences; events included a 40% eGFR decline or progression to kidney failure requiring dialysis or transplant.
39.2% of patients were on DCCBs, a widely used second-line blood pressure treatment, versus 60.8% using other antihypertensive drugs.
Researchers said DCCBs may raise pressure inside kidney filtering units by relaxing incoming blood vessels more than outgoing ones, potentially worsening damage despite modern kidney-protective therapy.
The ERA Congress study was observational, not proof of causation, but it raises questions about blood-pressure drug choice for millions of diabetic kidney disease patients and points to a need for randomized trials.
Is a widely used blood pressure drug silently worsening kidney disease for millions of diabetic patients?
With a popular medication now in question, what are the truly safe options for diabetic kidneys?
Major Study Finds 29–33% Higher Kidney Risk with DCCBs in Diabetic Kidney Disease Despite Modern Therapies
Overview
A large observational study presented at the European Renal Association Congress in June 2026 analyzed data from over 31,000 adults with type 2 diabetes and kidney disease who were already receiving standard kidney-protective therapies. About 39% of these patients were also prescribed dihydropyridine calcium-channel blockers (DCCBs), such as amlodipine or nifedipine. The study found that DCCB use was linked to a 29–33% higher risk of major adverse kidney events over a median follow-up of 3.5 years. These findings raise important questions about the safety of DCCBs in this high-risk group and highlight the need for further research.